SHANGHAI and MORRISVILLE, N.C., Dec. 18, 2024 /PRNewswire/ — Inceptor Bio, a leading innovator in cell therapy, and GRIT Bio, a clinical-stage immunotherapy developer, today announced a strategic partnership to advance IB-T101, a potentially best-in-class CAR-T therapy targeting solid tumors.
IB-T101, Inceptor Bio’s autologous CD70 CAR-T program, utilizes the proprietary OUTLAST™ platform to reprogram T cells for superior stemness, durability, and effector function in the hostile tumor microenvironment. The program targets clear cell Renal Cell Carcinoma (ccRCC), a cancer with significant unmet medical need and over 300,000 new cases annually worldwide.
“We are excited to partner with GRIT Bio to bring IB-T101 into the clinic and address the urgent need for effective solid tumor therapies,” said Dr. Matthias Schroff, CEO of Inceptor Bio. “This collaboration highlights the potential of our proprietary OUTLAST™ platform, and the data generated will play a critical role in advancing the program as we strive to deliver best-in-class therapies for patients.”
Dr. Mengyang Chong, Chief Business Officer of GRIT Bio, shared, “Partnering with Inceptor Bio allows us to bring a highly differentiated CAR-T program to patients. IB-T101 has the potential to transform the treatment landscape for solid tumors, and we are eager to contribute our expertise in clinical development and manufacturing to accelerate its progress.”
Under the terms of the agreement, Inceptor Bio will grant GRIT Bio an exclusive license for IB-T101 in China. GRIT Bio will oversee development, manufacturing, and commercialization. Inceptor Bio is eligible to receive milestone payments and royalties upon IB-T101 achieving certain response criteria and plans to leverage clinical data from this collaboration to support regulatory submissions and development in other regions.
This partnership represents a critical step in Inceptor Bio’s mission to validate the OUTLAST™ platform as a best-in-class approach for engineered T cell therapies and bring transformative treatments to patients worldwide.
About Inceptor Bio
Inceptor Bio, founded in May 2020 and headquartered in Research Triangle Park, NC, is dedicated to advancing next-generation cell and gene therapies to cure cancer. The company’s proprietary OUTLAST™ platform reprograms T cells to maintain stemness and effector function, addressing the unique challenges of treating solid tumors. Inceptor’s lead program, IB-T101, targets CD70 in clear cell Renal Cell Carcinoma (ccRCC) and represents a potentially best-in-class therapy. With a strong leadership team and strategic partnerships, Inceptor Bio is committed to advancing a pipeline of cutting-edge therapies to improve outcomes for patients with limited treatment options globally.
About GRIT Bio
Founded in 2019, GRIT Biotechnology is a leading cell therapy company dedicated to delivering transformative cancer treatments. GRIT specializes in Tumor-Infiltrating Lymphocyte (TIL) therapies, leveraging its proprietary technology platforms—StemTexp®, StaViral®, KOReTIL®, and ImmuT Finder®—to develop next-generation gene-edited TIL products.With over 100 experienced professionals and a state-of-the-art GMP manufacturing facility, GRIT is advancing a robust pipeline of innovative cell therapies designed to address the unmet needs of solid tumor patients.
https://www.prnewswire.com/news-releases/inceptor-bio-and-grit-bio-announce-strategic-partnership-to-advance-ib-t101-a-next-generation-solid-tumor-car-t-utilizing-the-outlast-platform-302334271.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
[2024/12/27] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GEMMABio Pioneers Affordable Gene Therapies with $34M Seed Funding
Gene therapy startup GEMMABio, led by industry trailblazer Jim Wilson, has secured $34 million in seed funding to transform treatment options for rare diseases. Wilson, formerly of the University of Pennsylvania, founded GEMMABio and Franklin Biolabs earlier this...
Genethon Highlights Key Developments in Gene Therapy Research
December 19, 2024 – Paris, France – Genethon, a pioneering non-profit gene therapy research and development organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has unveiled significant progress in its clinical and scientific endeavors as...
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
– GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S....
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
